UPLOAD Filing
Lyell Immunopharma, Inc.
Date: Aug. 13, 2025 · CIK: 0001806952 · Accession: 0000000000-25-008503
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289539
Letter
Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed August 12, 2025 File No. 333-289539 Dear Lynn Seely:
August 13, 2025
Lynn Seely President and Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Asa M. Henin
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 13, 2025 Lynn Seely President and Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, CA 94080 Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed August 12, 2025 File No. 333-289539 Dear Lynn Seely: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Asa M. Henin </TEXT> </DOCUMENT>